So which researcher is going to follow this up and test it for stroke? Or are we going to have to tell our doctors the day after the stroke that we want this and damn the consequences? The dissertations I've seen answer better questions than standard researchers.
Abstract
Traumatic Brain Injury (TBI) is a leading cause of death and
disability in the United States for which there are no federally
approved pharmacological treatments. Preclinical trials with
nicotinamide (NAM) and progesterone (Prog) treatment demonstrate
beneficial neuroprotection and recovery of function following TBI. The
primary goal of this study was to assess both neuroprotection and
recovery of function in an animal model of TBI after combination
treatment of both NAM and Prog. Animals received a cortical contusion
injury over the sensorimotor cortex and were treated with either
nicotinamide (75 mg/kg, i.p. NAM loading dose, 12 mg/kg/hr NAM, s.c.
over 72 hrs), Prog (10 mg/kg Prog, i.p. over 72 hrs), NAM and Prog(75
mg/kg, i.p. NAM loading dose, followed by continuous infusion of 12
mg/kg/hr NAM, s.c. over 72 hrs; 10 mg/kg Prog, i.p. over 72 hrs) or
Vehicle (75 mg/kg, i.p. sterile saline loading dose, followed by
continuous infusion 12 mg/kg/hr sterile saline, s.c. over 72 hrs; 10
mg/kg peanut oil, i.p. over 72 hrs), and compared to a craniotomy only
(Sham) group. Following this regimen they were assessed in a battery of
behavioral (fine and gross motor, sensory, and cognitive) tasks or a
histological assessment at 24 hrs post-injury assessing lesion cavity
size, degenerating neurons, and reactive astrocytes. Our results
replicate the beneficial effects of treatment with either NAM or Prog
demonstrating significant improvements in recovery of function, and a
reduction in lesion cavitation, degenerating neurons and reactive
astrocytes 24 hours post-injury. The combination treatment of NAM and
Prog led to a significant improvement in both neuroprotection at 24 hrs
post-injury and recovery of function in sensorimotor related tasks when
compared to each individual treatment (NAM or Prog). It is suggested
here that further preclinical trials using NAM and Prog as a combination
treatment should be done to identify any drug interactions,
pharmacokinetics, and a new window of opportunity and proper dosing of
this combination treatment.
No comments:
Post a Comment